Literature DB >> 25898737

[Caspases participarion in the cell death induced by GD2-specific monoclonal antibody].

P A Vishniakova, I I Doronin, I V Holodenko, D Iu Riazantsev, I M Molotkovskaia, R V Holodenko.   

Abstract

The participation of the main caspases in the cytotoxic effects induced by monoclonal antibody 14G2a specific against tumor-associated ganglioside GD2 was studied in the EL-4 cells. It has been found constitutive expression ofprocaspases genes in the EL-4 cells; incubation of the cells with 14G2a antibodies didnot result in increasing of the procaspases expression. Weak enzymatic activity of caspases has been shown using fluorescent labeled substrates. At the same cell death level, activity of caspase-3 and caspase-9 in the cells incubated with 14G2a was about 7.5- and 3-fold lower than in cells after incubation with staurosporine. Pan caspase inhibitor Z-VAD-FMK, and caspase-3 inhibitor reduced the cytotoxic effects induced by 14G2a at 9-16 and 6-13%, respectively. At the same conditions, pan caspase inhibitor decreased staurosporine-induced apoptosis at 55-65%. Inhibitors of other caspases had no effect on the cell death triggered by the antibodies. Inhibition analysis demonstrated also that caspases did not involved in the cell volume decreasing and permeabilization of the cell plasma membrane, which were the first stages of anti-GD2-mAb-induced cell death in the EL-4 cells. Thus, despite the slight activation of caspases during the cell death induced by antibodies directed to GD2, they do not play a key role and do not determine the mechanism of cell death triggered through the tumor-associated ganglioside GD2.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25898737

Source DB:  PubMed          Journal:  Bioorg Khim        ISSN: 0132-3423


  1 in total

1.  Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors.

Authors:  Daniel V Kalinovsky; Alexey V Kibardin; Irina V Kholodenko; Elena V Svirshchevskaya; Igor I Doronin; Mariya V Konovalova; Maria V Grechikhina; Fedor N Rozov; Sergey S Larin; Sergey M Deyev; Roman V Kholodenko
Journal:  J Immunother Cancer       Date:  2022-06       Impact factor: 12.469

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.